Silo Pharma, Inc. (SILO)
NASDAQ: SILO · Real-Time Price · USD
2.400
-0.050 (-2.04%)
At close: Sep 4, 2026, 4:00 PM EDT
2.280
-0.120 (-5.00%)
After-hours: Sep 4, 2026, 7:39 PM EDT
Silo Pharma Revenue
Silo Pharma had revenue of $54.08K in the twelve months ending June 30, 2026, down -25.00% year-over-year. In the year 2025, Silo Pharma had annual revenue of $72.10K.
Revenue (ttm)
$54.08K
Revenue Growth
-25.00%
P/S Ratio
70.49
Revenue / Employee
$18,026
Employees
3
Market Cap
3.81M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 72.10K | - | - |
| Dec 31, 2024 | 72.10K | - | - |
| Dec 31, 2023 | 72.10K | - | - |
| Dec 31, 2022 | 72.10K | 838.00 | 1.18% |
| Dec 31, 2021 | 71.26K | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| PMGC Holdings | 2.58M |
| GeoVax Labs | 852.28K |
| Onconetix | 645.82K |
| BioRestorative Therapies | 357.87K |
| Addex Therapeutics | 136.51K |
| VivoSim Labs | 112.00K |
| Alaunos Therapeutics | 3.00K |
SILO News
- 19 days ago - Silo Pharma receives notice of allowance from CIPO for PTSD treatment - TheFly
- 19 days ago - Silo Pharma Receives Notice of Allowance for Canadian Patent Application for Novel PTSD Treatment - GlobeNewsWire
- 27 days ago - Silo Pharma granted European patent covering PTSD therapy - TheFly
- 4 weeks ago - Silo Pharma Subsidiary QwikAgents Collaborates with Amazon Web Services Premier Tier Partner Caylent to Advance Enterprise AI Platform - GlobeNewsWire
- 6 weeks ago - Silo Pharma files to sell 1.91M shares of common stock for holders - TheFly
- 6 weeks ago - Silo Pharma Advances Growth Platforms for AI Agent Commercialization and Lead PTSD Drug Program - GlobeNewsWire
- 7 weeks ago - Silo Pharma subsidiary QwikAgents joins AMD AI program - TheFly
- 7 weeks ago - Silo Pharma's QwikAgents Joins AMD AI Developer Program to Advance Enterprise AI Agent Platform - GlobeNewsWire